Evgen Pharma plc (EVG.L) LSE

0.82

+0.018(+2.25%)

Updated at April 24, 2024 04:24PM

Currency In GBp

Evgen Pharma plc

Address

Alderley Park, Block 24

Nether Alderley, SK10 4TG

United Kingdom of Great Britain and Northern Ireland

Phone

44 16 2546 6591

Sector

Healthcare

Industry

Biotechnology

Employees

10

First IPO Date

October 21, 2015

Key Executives

NameTitlePayYear Born
Dr. Huw Jones BSc, Ph.D.Chief Executive Officer & Executive Director304,7301959
Mr. Toni HaenninenChief Financial Officer & Director01977
Dr. Helen KuhlmanChief Business Officer0N/A
Dr. Glen Clack FFPM, M.D.Chief Medical Officer0N/A

Description

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.